Pfizer ends development of oral GLP1 Danuglipron
Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
GLP1 Receptor Agonists are very valuable drugs, both to consumers who want help with weight management or type 2 diabetes, and companies that are looking for profitable drug candidates. Despite this, not every GLP1 formulation makes it to market.
Check out our quick explainer
While intense competition can breed higher quality drugs, it can cause overlooking of deficiencies in existing formulations in a rush to get to market. Thanks to vigilance on the part of (and likely some competitive pressures), Danuglipron is not one of those cases.
The end of Danuglipron as a possible future GLP1 that increases accessibility and drives down prices is regrettable, but the continuation of GLP1 as an incredibly safe and well-researched choice for weight management and treatment of type 2 diabetes is worth celebrating.
Want to ready the reasons we found as to why Danuglipron is no longer developed? The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
